# Study of Immunogenicity Equivalence of a Homologous Third Dose of Covid-19 (Recombinante) Vaccine

> **NCT05142488** · PHASE4 · UNKNOWN · sponsor: **The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)** · enrollment: 662 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** Covid -19 (recombinante) vaccine

## Key facts

- **NCT ID:** NCT05142488
- **Lead sponsor:** The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-11-09
- **Primary completion:** 2022-03-30
- **Final completion:** 2023-03-30
- **Target enrollment:** 662 (ESTIMATED)
- **Last updated:** 2021-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05142488

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05142488, "Study of Immunogenicity Equivalence of a Homologous Third Dose of Covid-19 (Recombinante) Vaccine". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05142488. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*